In order to understand the treatment results, it is important to understand two key biomarkers that we use to measure the success of the treatment.
HSP70 is our key biomarker for the Chaperone Protein Axis (CPA). As we get older our axis starts slowing down inside the cell, which leads to protein accumulation and alteration in translation of mRNA to Functional Proteins. This, in turn, slows the cell’s metabolism and has a significant effect on our body’s ability to function and fight disease states. The cells become slightly “porous” and HSP70 leaks out into our blood stream. In short, as we age, our circulating HSP70 increases, as our cells become impaired.
As long as there is no ongoing clinical disease, Chaperonze treatment creates cell stabilization. CPA treatment increases HSP70 production inside the cell, stabilizing the cell, repairing the cell, and leading to a decrease in circulating HSP70.
We use IGF-1 as the key biomarker of the Somatotrophic (Growth Hormone) Axis. Through our research and clinical studies, we have found evidence that has led us to firmly believe that, overall, as your cellular health increases, so too will your key hormonal function. We know that IGF-1 decreases with age and our research and studies have also led us to believe that this is due to an overall decrease in cellular function. The IGF-1 is somewhat inhibited from being translated in the cell and so decreases in physiologic functionality.